No Data
No Data
Chengyitong (300430.SZ): The core product automated biological fermentation control system has many applications in the field of synthetic biology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Are there synthetic biological-related technologies currently being developed by the company?” The company replied that downstream customers in the company's intelligent manufacturing sector mainly include pharmaceutical and biological manufacturing companies. Biomaneling is mainly a production method using synthetic biotechnology as an important technical support and biological fermentation process as an important means of implementation. The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology. Driven by synthetic biotechnology and green biological manufacturing, 202
Chengyitong (300430.SZ): Currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of invasive technology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Can the brain-computer products the company is developing regenerate insulin to treat diabetes?” The company replied that currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of intrusive technology. In planning non-invasive technology, the company integrates existing rehabilitation products with brain-computer interfaces to achieve product upgrades, thereby providing more effective rehabilitation services for patients with neurological diseases. In the future, the company will also focus on the application of brain-computer interfaces in other medical fields
Express News | Chengyitong: The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology
Chengyitong (300430): Combining Internal and External Construction and Consolidation of Intelligent Manufacturing Brain-Computer Interfaces to Empower Rehabilitation Medicine
Incident: The company released its 2024 annual report and quarterly report. The company achieved operating income of 1,176 billion yuan (+20.63%) in 2023; net profit attributable to shareholders of listed companies was 170 million yuan (+36.
Chengyitong (300430.SZ) announced first-quarter results, net profit of 307.813 million yuan, an increase of 37.71%
Chengyitong (300430.SZ) released its report for the first quarter of 2024, achieving 2.68 operating income during the reporting period...
Dongfang Wealth Securities released a research report on April 24 stating that Chengyitong (300430.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) intelligent manufacturing: “internal and external development” pro
Dongfang Wealth Securities released a research report on April 24 stating that Chengyitong (300430.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) intelligent manufacturing: “internal and external development” promotes development, and project operation efficiency has improved markedly; 2) rehabilitation medicine: a deep focus on “brain-computer interface”, and the rural division is progressing steadily; 3) R&D investment has been further increased to enable pharmaceutical production; 4) the cost level has decreased slightly and profitability has increased. (Mainichi Keizai Shimbun)
No Data